AzTrials
AzTrials

Myocardial InfarctionNCT00399503

Assessment of Noninvasive Methods to Identify Patients at Risk of Serious Arrhythmias After a Heart Attack

An observational study of Myocardial Infarction and Death, Sudden, Cardiac, run by University of Calgary at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study evaluates the usefulness of noninvasive tests of the structure of the heart and the nervous system controlling the heart. It will assess whether combining tests that evaluate heart structure with others that measure the nervous system controlling the heart will identify most patients who develop serious… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Spectral T Wave Alternans, Modified Moving Average T Wave Alternans and Baroreceptor Sensitivity
Type of treatment
Surgery or procedure
How many people
350 participants
Where
1 siteCanada
Study dates
Sep 2001to Dec 2007
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Confirmed MI <31 days, based upon elevated cardiac-specific CK (total CK-MB mass >7ng/mL or CK-MB/total CK ≥ 2.5%) or troponin-T (> 0.1 ng/ml)144) plus
  • clinical symptoms or ECG evidence of myocardial injury (ST deviation ≥ 1 mm in 2, contiguous leads or new/previously undocumented Q waves)144, \&
  • left ventricular ejection fraction ≤ 0.40 within 48 hrs or ≤ 0.50 beyond 48 hrs of MI using (echocardiography, radionuclide or contrast angiography) \&
  • Sinus rhythm at the time of enrollment.

Who cannot join

  • Geographic isolation or inability to return for follow-up,
  • Comorbid illness likely to cause death within 24 months,
  • Inability to complete a submaximal exercise test (e.g., urgent CABG),
  • Class I indication for a defibrillator (e.g., VF or sustained VT > 48 hours of index MI), or
  • Lack of written informed consent

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Foothills Hospital

    Calgary, Alberta, T2N4N1

Other trials in Canada

About this study

Official title: Risk Estimation Following Infarction Noninvasive Evaluation (REFINE)

This study evaluates the usefulness of noninvasive tests of the structure of the heart and the nervous system controlling the heart. It will assess whether combining tests that evaluate heart structure with others that measure the nervous system controlling the heart will identify most patients who develop serious heart rhythm problems after a heart attack.

Read the detailed description

Background. Sudden cardiac death (SCD) kills >450,000 North Americans each year. Patients with a history of myocardial infarction (MI) are at particular risk. Concurrent alterations in myocardial structure \& autonomic tone appear important for the development of the arrhythmias leading to SCD.

Given the grave consequences of SCD, an ideal testing procedure should identify most of those at risk (sensitive) \& correctly classify risk (accurate). Since >90% of patients who suffer serious arrhythmias post-MI have at least mild left ventricular (LV) dysfunction (ejection fraction [EF] <0.50) this is an optimal group to study.

While noninvasive tests have been developed to estimate SCD risk, prior approaches have failed to: 1) identify the majority of patients at risk for serious arrhythmias (insensitive), 2) evaluate temporal changes in parameters, 3) identify the optimal timing for risk assessment post-MI, \& 4) develop a widely-applicable screening tool. This has resulted in a failure to delivery effective therapies (e.g., defibrillator) in a cost-effective manner.

Hypotheses. Primary: Concurrent evaluation of electrical structure \& autonomic tone will accurately identify most post-MI patients at risk of serious arrhythmic events. Secondary: 1) assessment later (16 weeks) provides more prognostic information than assessment early post-MI (4 weeks), 2) a single multi-parameter test procedure can be developed, and 3) individually, repolarization alternans provides the most prognostic information.

Methods. 350 persons with a recent MI (<31 days) \& EF <0.50 will undergo testing early (4 weeks), intermediate (8 weeks) \& late (16 weeks) post-MI.

Four techniques assess cardiac structure (spectral T-wave alternans [TWA], modified moving average TWA; signal-averaged [SA] ECG) \& nuclear ejection fraction. Three others evaluate autonomic tone (baroreceptor sensitivity [BRS], heart rate variability [HRV], and Heart Rate Turbulence [HRT]).

Data Collection \& Outcomes. Patients will be recruited over 24 months \& followed biannually for four years. Committee (blinded) endpoint classification \& central laboratory data analysis will be utilized. A composite of resuscitated cardiac arrest and cardiac mortality is the primary outcome. The components (resuscitated / non-resuscitated cardiac arrest and cardiac death) are secondary outcomes.

Statistical Aspects \& Sample Size. Standard methods of description \& analysis will be used. The capacity to accurately identify most patients at risk for serious arrhythmias will be evaluated using Cox multivariate models. The primary model will include age, sex, EF at 8 wks \& important baseline medication use.

Since multivariate modeling requires lower (more sensitive) dichotomy limits the following will be used: spectral TWA positivity will be defined as a non-negative test. SA-ECG QRS width >104 msec will be labeled as abnormal. For HRV, SDNN values <105 msec will be considered abnormal. For BRS, values <6.1 msec per mmHg will indicate impairment. For HRT abnormalities in T-onset \& / or T-slope will be considered abnormal. Receiver operating characteristic curves will be used to identify a cut-point for modified moving average TWA.

Assuming a 5 year 20% rate of the composite arrhythmias in patients with positive test results, we have 85% power to detect a 2.5-fold higher risk in patients with abnormalities than those without these abnormalities.

Relevance. This is the first large prospective study to evaluate the utility of concurrent structural \& autonomic tone assessment in predicting the development of serious arrhythmias after an MI.

Being tested
Spectral T Wave Alternans, Modified Moving Average T Wave Alternans, Baroreceptor Sensitivity, Heart Rate Variability, Heart Rate Turbulence
Keywords
Noninvasive assessment, Combined parameter, Holter
Medical subject headings
Myocardial Infarction, Death, Sudden, Cardiac, Death

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Spectral T Wave AlternansProcedure or surgery

  • Modified Moving Average T Wave AlternansProcedure or surgery

  • Baroreceptor SensitivityProcedure or surgery

  • Heart Rate VariabilityProcedure or surgery

  • Heart Rate TurbulenceProcedure or surgery

  • Deceleration CapacityProcedure or surgery

  • Signal Averaged ECGProcedure or surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Nov 2006 (estimated)
  2. Study startSep 2001
  3. Primary completionDec 2007
  4. Study completionDec 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
350 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00399503
Sponsor's protocol ID
CIHR 73-1518
Other IDs
HSFA 73-1220
Status last verified
Nov 2006
First submitted
13 Nov 2006
Last updated
14 Jun 2016
Results posted
No

Publications

  • Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, Noullett C, Van Schaik A, Mitchell RT, Shibata MA, Gulamhussein S, McMeekin J, Tymchak W, Schnell G, Gillis AM, Sheldon RS, Fick GH, Duff HJ; REFINE Investigators. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol. 2007 Dec 11;50(24):2275-84. doi: 10.1016/j.jacc.2007.08.042. Epub 2007 Nov 26.

    PubMed 18068035
  • Slawnych MP, Nieminen T, Kahonen M, Kavanagh KM, Lehtimaki T, Ramadan D, Viik J, Aggarwal SG, Lehtinen R, Ellis L, Nikus K, Exner DV; REFINE (Risk Estimation Following Infarction Noninvasive Evaluation); FINCAVAS (Finnish Cardiovascular Study) Investigators. Post-exercise assessment of cardiac repolarization alternans in patients with coronary artery disease using the modified moving average method. J Am Coll Cardiol. 2009 Mar 31;53(13):1130-7. doi: 10.1016/j.jacc.2008.12.026.

    PubMed 19324258

Questions about this trial

What is this clinical trial studying?

An observational study of Myocardial Infarction and Death, Sudden, Cardiac, run by University of Calgary at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00399503, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jun 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in